Abstract Adalimumab is a frequently prescribed TNFα inhibitor for treatment of rheumatoid arthritis. We report on a patient who probably developed a Miller-Fisher syndrome after the second injection of adalimumab.
Introduction
Rheumatoid arthritis (RA) is a common chronic arthropathy affecting ≈1% of the adult population worldwide. Tumor necrosis factor alpha (TNFα) inhibitors have been increasingly used as DMARD therapy in conjunction with conventional drugs, in particular methotrexate. Adalimumab is a widely prescribed TNFα inhibitor. We report on a female patient with RA who developed Miller-Fisher syndrome [1] after the second injection of adalimumab.
Case presentation
The patient, a 77-year-old female with seropositive erosive RA, had previously received hydroxychloroquine, gold salts, penicillamine, sulfasalazine, and cyclosporine without success. Methotrexate had to be discontinued because of drug-induced pneumonitis. As a result, she was maintained on azathioprine (75 mg/day=1 mg/kg) and prednisone (5 mg/ day). In 2006, she underwent a cervical laminectomy C4-C5 and C6-C7 with plate from C4 to C6 because of a myelopathy secondary to cervical osteoarthritis. At surgery, there was no local rheumatoid pannus. Her medical history included type II diabetes mellitus, hypertension, hyperlipidemia and ischemic heart disease.
In 2007, she was started on adalimumab after a RA flare. Twenty-four hours after the second injection of 40 mg of adalimumab, she reported dizziness and loss of cutaneous sensation that progressed proximally in the lower limbs and she was hospitalized. On admission, the general examination was unremarkable except for mild fever. The neurological examination showed ataxia of all four limbs and disappearance of the deep tendon reflexes in the lower limbs. The next day, there was a complete loss of proprioception, loss of balance and impossibility to walk. One week later, she developed a horizontal nystagmus with impossibility to lift the upper eyelids [1, 2] .
Laboratory tests showed a raised ESR (40 mm in the first hour) and CRP (69 mg/l). Autoantibodies including antiganglioside antibodies (GQ1b) were negative. The search for an infection was negative.
Radiological investigations included a cerebral and a thoraco-abdo-pelvic computed tomography, and a cervical to lumbar spine MRI; they were all normal. The electromyogram showed a decreased evocated sensitive response to peripheral nerve stimulation on the upper limbs and absence of this response on the lower limbs. The motor recording was normal. There was no muscle involvement. A diagnosis of a Miller-Fisher syndrome [1, 2] was made.
Treatment consisted of high-dose steroids (75 mg/day= 1 mg/kg), gabapentine, and an increased dose of azathioprine (75 mg tad). Physical therapy was initiated. The biological signs of inflammation disappeared quickly but the clinical evolution was marked by a slow improvement over one year of balance, proprioception, and reflexes.
Discussion
The Miller-Fisher syndrome [1, 2] is an autoimmune polyneuropathy characterized by an ascending muscle weakness of the limbs, as in the Guillain-Barré syndrome, with loss of sensation, areflexia, ataxia, and opthalmoplegia. Although neurological symptoms have been reported with adalimumab [3] , this case reports, to our knowledge, on the first Miller-Fisher syndrome induced by treatment with adalimumab. Immunological mechanisms have been incriminated in the development of this syndrome, though in our case, anti-ganglioside antibodies were absent. The lumbar puncture showed an isolated increased protein content (1,000 mg/l) but the patient underwent a cervical surgery a few weeks before.
Neurological complications have been described with several TNFα inhibitors. The use of lenercept in multiple sclerosis produced worsening of the disease causing the premature interruption of the study [4] . Similarly, 17 patients treated with etanercept [3] and two patients treated with infliximab [3] developed neurological symptoms. These latter included confusion, ataxia, dysesthesia, paresthesia, facial paralysis, optical neuritis, hemiparesia, transverse myelitis and an ascending neuropathy resembling the Guillain-Barré syndrome. All these cases were proven by a retrial of the drug. The risk was estimated for etanercept (31 cases for 100,000 patients) and infliximab (41 cases for 100,000) [3] . No case has been described with adalimumab until now. Therefore, a Miller-Fisher syndrome secondary to the use of a TNFα inhibitor seems to be a class effect, which can be, as in our case, rapidly and severely progressive.
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